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ABSTRACT
Background
Ulcerative colitis (UC) and Crohn’s disease (CD) are polygenic chronic inflammatory bowel
diseases (IBD) of high prevalence that are associated with considerable morbidity. The
hedgehog (HH) signalling pathway, which includes the transcription factor glioma-associated
oncogene homolog 1 (GLI1), plays vital roles in gastrointestinal tract development, homeo-
stasis, and malignancy. We identified a germline variation in GLI1 (within the IBD2 linkage
region, 12q13) in patients with IBD. Since this IBD-associated variant encodes a GLI1 protein
with reduced function and our expression studies demonstrated down-regulation of the HH
response in IBD, we tested whether mice with reduced Gli1 activity demonstrate increased
susceptibility to chemically induced colitis.
Methods and Findings
Using a gene-wide haplotype-tagging approach, germline GLI1 variation was examined in
three independent populations of IBD patients and healthy controls from Northern Europe
(Scotland, England, and Sweden) totalling over 5,000 individuals. On log-likelihood analysis,
GLI1 was associated with IBD, predominantly UC, in Scotland and England (p , 0.0001). A
nonsynonymous SNP (rs2228226C!G), in exon 12 of GLI1 (Q1100E) was strongly implicated,
with pooled odds ratio of 1.194 (confidence interval¼1.09–1.31, p¼0.0002). GLI1 variants were
tested in vitro for transcriptional activity in luciferase assays. Q1100E falls within a conserved
motif near the C terminus of GLI1; the variant GLI protein exhibited reduced transactivation
function in vitro. In complementary expression studies, we noted the colonic HH response,
including GLI1, patched (PTCH), and hedgehog-interacting protein (HHIP), to be down-
regulated in patients with UC. Finally, Gli1
þ/lacZ mice were tested for susceptibility to dextran
sodium sulphate (DSS)-induced colitis. Clinical response, histology, and expression of
inflammatory cytokines and chemokines were recorded. Gli1
þ/lacZ mice rapidly developed
severe intestinal inflammation, with considerable morbidity and mortality compared with wild
type. Local myeloid cells were shown to be direct targets of HH signals and cytokine expression
studies revealed robust up-regulation of IL-12, IL-17, and IL-23 in this model.
Conclusions
HH signalling through GLI1 is required for appropriate modulation of the intestinal response
to acute inflammatory challenge. Reduced GLI1 function predisposes to a heightened myeloid
response to inflammatory stimuli, potentially leading to IBD.
The Editors’ Summary of this article follows the references.
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Ulcerative colitis (UC; Mendelian Inheritance in Man [MIM]
191390) and Crohn’s disease (CD; MIM 266600) are chronic,
relapsing, inﬂammatory bowel diseases (IBD) of high preva-
lence (200–400 cases per 100,000 in Northern Europe and
North America [1]) and are associated with considerable
morbidity. Precise aetio-pathogenetic mechanisms are not
understood but several lines of evidence implicate the central
importance of a dysregulated host response to intestinal
bacteria [2]. Epidemiological data, detailed molecular studies,
and recent genome-wide association studies strongly suggest
that UC and CD are related polygenic diseases that share some
susceptibility loci (IL-23R, IL-12B, and NKX2.3), but differ at
others: NOD2, ATG16L1, and IRGM are speciﬁc CD genes; the
ECM1 locus is associated with UC [3–10]. The IBD2 locus
(Online Mendelian Inheritance in Man [OMIM] 601458) on
Chromosome 12q13 was ﬁrst identiﬁed in a UK genome-wide
linkage scan (peak LOD score 5.47 at D12S83) [11] involving
both UC and CD patients. Later studies showed that IBD2
contributes signiﬁcantly to UC, notably extensive disease, but
perhaps in a lesser way to CD susceptibility [12,13].
A strong candidate gene that maps to the IBD2 locus is
GLI1, one of three related GLI transcription factors that
transduce secreted hedgehog (HH) signals. HH signalling is
key in gut development, homeostasis, and malignancy, but has
not been carefully studied in IBD [14]. In developing
intestine, Sonic (SHH) and Indian Hedgehog (IHH) provide
a paracrine signal from epithelium to the mesenchymally
expressed receptor patched (PTCH) [14]. The binding of HH
to PTCH releases the membrane protein smoothened (SMO)
from inhibition and allows HH signal transduction through
the zinc ﬁnger transcription factors glioma-associated onco-
gene homolog 1 (GLI1), GLI2, and GLI3 to direct tissue
patterning and cell fate (Figure S1) (see [14] and citations
therein). Chronic injury, inﬂammation, and repair are critical
aspects of IBD, and thus it is pertinent that the HH pathway is
centrally involved in these processes in several other tissues,
including muscle [15], liver [16,17], and lung [18,19]. Indeed,
HH signalling may play a central role in the inﬂammatory
response since SHH is critical for T lymphocyte development
[20], adult human CD4þT cell activation [21,22], and myeloid
cell maturation in the spleen [23]. Furthermore, SHH has
recently been suggested to be a direct transcriptional target
of NF-jB [24]. Dysregulation of components of the HH
pathway has also been noted in inﬂammatory diseases of the
gut, including Barrett oesophagus, chronic gastritis, and IBD
[25]. Using microarray gene expression analyses of colono-
scopic biopsies, we recently demonstrated that GLI1 expres-
sion is greater in the distal compared with the proximal
colon, and is down-regulated in the intestinal mucosa in
inﬂamed UC compared with noninﬂamed samples [26].
Taken together, these studies suggested a possible associ-
ation between GLI1 and IBD susceptibility, and we set out to
directly test this possibility in both human disease and
murine model systems. Our main initial objectives were to
ascertain, from human genetic association study data,
whether germline GLI1 variation was associated with IBD,
and to describe the expression of HH signalling components
in colonic inﬂammation in humans. These results led us to
hypothesize that a reduced dosage of functional GLI1 protein
might play an important role in colonic inﬂammation. To test
this hypothesis directly, we challenged Gli1
þ/lacZ mice and
their wild-type (WT) littermates with dextran sodium
sulphate (DSS) to induce acute intestinal inﬂammation, and
monitored clinical and histological parameters, cytokine
proﬁles, and cellular targets of HH signalling in vivo.
Methods
Written, informed consent was obtained from all patients
and controls. The study protocol was approved by the
Lothian Research and Ethics Committee (LREC-2000/4/192
and 2004/S1103/22); Cambridge (LREC-01/418; MREC-03/5/
012); and Regional Ethics Committee, Karolinska Institutet.
Participants and Samples
Individuals for genotyping. In Scotland the population
consisted of 817 IBD cases (474 UC; 335 CD; eight colonic IBD
type unclassiﬁed [IBDU]) and 1,374 healthy controls (HC)
(Table 1). Diagnosis was made by clinical, radiological, and
histopathological means, adhering to the criteria of Lennard-
Jones [27]. All IBD patients attended the clinic at the Western
General Hospital (Edinburgh, Scotland), a tertiary referral
centre for IBD in southeast Scotland. The population was
98.5% white, non-Jewish. The median age at diagnosis was
31.0 y (IQR 23.3–46.0). Controls were recruited from across
Scotland; median age was 50.0 (IQR 43.0–55.0), ethnicity
.99% white, non-Jewish, and 48.7% male sex.
In Cambridge, England 1,748 unrelated Caucasian IBD
patients (Lennard-Jones criteria) of northern European
origin attending IBD clinics in East Anglia, UK were recruited
c o m p r i s i n g9 2 8U C ,7 3 7C D ,a n d8 3w i t hI B D U .T h e
population was .99% white, non-Jewish. The 589 ethnically
and geographically matched HCs were previously recruited in
East Anglia for the European Prospective Investigation of
Nutrition and Cancer (EPIC). Median age of controls was 60 y.
In Sweden 288 UC and 205 CD patients (Lennard-Jones
criteria) were recruited from various hospitals in Stockholm
County. 281 Swedish HC were healthy volunteers from the
Karolinska University Hospital staff (n ¼ 170) and orthopae-
dic day-case surgery patients (n ¼ 111) with no previous
medical conditions. Cases and controls were .99% white,
non-Jewish.
Phenotyping. Phenotypic data were collected by patient
questionnaire, interview, and case note review, and classiﬁed
according to Montreal criteria (Table 1) [28].
Genotyping
Scotland and Sweden. Genomic DNA was extracted from
blood samples using a modiﬁed salting-out technique as
previously described, and Nucleon kits. Genotypes were
derived using the Taqman system for allelic discrimination;
the assays were available from Applied Biosystems as Taqman
SNP Genotyping Assays (7900HT sequence detection system;
Applied Biosystems), except for SNPs rs10783819, rs3809114,
rs507562, rs542278, rs730560, rs1669296, and rs775322, which
were genotyped on the Illumina platform. The accuracy of
each Taqman assay was checked by repeat analysis in 5% of
cases, with 100% concordance. Genotype distributions in all
populations were consistent with Hardy-Weinberg equili-
brium (HWE) (p . 0.01) for all SNPs. For the four tagging
SNPs (tSNPs) that could not be derived by Taqman, genotypes
were obtained by direct sequencing.
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Genotyping of CD cases and controls was performed using
the Taqman biallelic discrimination system using an ABI
7900HT analyser (Applied Biosystems). Genotyping of UC
cases was performed using a 1,536-SNP Golden Gate bead
array (Illumina). Concordance between platforms was as-
sessed by genotyping 92 UC cases for SNPs rs2228224 and
rs2228226 with concordance rates of 100% and 97.9%
respectively and no evidence of systematic bias between
platforms. Genotype distributions in case and control
populations were consistent with HWE (p . 0.01) for all SNPs.
Gene Expression by Microarray and Quantitative Reverse-
Transcription PCR
The cohort of patients used in the microarray studies
consisted of 67 patients with UC, 53 with CD, and 31 HCs. For
UC patients, eight were recruited at diagnosis (treatment
naı ¨ve), 18 had active disease, and 41 quiescent disease; ten
were on systemic corticosteroid therapy, 11 on immunosup-
pressants (azathioprine, mercaptopurine, or methotrexate),
and 40 on 5-amino salicylic acid (5-ASA) therapy. Four of 53
patients with CD were on corticosteroids, 13 of 53 on
immunosuppressants, and 21 of 53 on a 5-ASA. Eight of 31
HC had non-IBD inﬂammation: two scattered lymphoid
aggregates with history of gastroenteritis, two microscopic
colitis, one pseudomembranous colitis, one diverticulitis, one
amoebiasis, and one eosinophilic inﬁltrate.
The assessment of RNA quality and integrity was per-
formed for the microarray experiments as follows: the
ampliﬁed cRNA was puriﬁed using the RNeasy Mini Kit
protocol (Qiagen) and 1 ll of ampliﬁed cRNA was quantiﬁed
using the NanoDrop ND-1000 Spectrophotometer. The
distribution of log intensities for each sample was plotted
and outlier samples (i.e., greater than two standard deviations
from the mean) were excluded from analysis. For additional
demographics, phenotyping, and full methodology pertaining
to the generation of the microarray dataset and quantitative
reverse-transcription PCR (QPCR) see Noble et al [26].
Induction of DSS-Induced Colitis and Histological Analysis
Groups of two to four WT Gli1
þ/lacZ or WT littermate
controls in mixed cages (bred at least three generations onto
a C57BL/6 background) were administered 3% DSS in
drinking water for 4–6 d. The amount of DSS consumed
was not signiﬁcantly different between WT and Gli1
þ/lacZ
animals (unpublished data). Gli1
þ/lacZ animals tended to weigh
more than their WT littermates (mean, 28 g for Gli1
þ/lacZ
animals and 24 g for WT animals). Therefore, DSS-treated
weight matched WT C57Bl/6 animals (n ¼ 4) were also tested
along with Gli1
þ/lacZ animals and WT littermates. No differ-
ences were evident between WT littermates and weight
matched C57Bl/6. All animals were monitored daily for
diarrhoea, bloody stool, and weight loss. Clinical scoring
was as follows: 0, no symptoms; 1, diarrhoea; 2, bloody stool; 4,
severe rectal bleeding and morbidity to the point of
immobility/death. For histology, a segment of large intestine
tissue of equal length and location for all animals was ﬁxed
overnight in 4% paraformaldehyde, dehydrated, inﬁltrated
with parafﬁn, and sectioned at 5 lm. The remaining colonic
tissue was taken for RNA analysis or frozen sectioning and
Gli1-LacZ expression analysis. Slides were stained with
haematoxylin/eosin and scored histologically by a gastro-
intestinal pathologist (H.D.A.) blinded to the source of the
tissue. Colitis scores were calculated using published methods
[29].
Gli1-LacZ Immunohistochemistry
Colonic tissue was dissected out in cold PBS and ﬁxed for
30 min in 4% PFA at 4 8C. After a brief rinsing in PBS, the
tissue was incubated in 30% sucrose/PBS at 4 8C overnight
and then embedded in OCT and frozen on dry ice.
Immunohistochemistry was performed on 8- to 10-lm
frozen sections. Sections were dried, rinsed in PBS, and
blocked for 1 h in 10% normal goat serum, 0.1% BSA, and
0.3% Triton-X in TBS (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl). Antibodies used were: hamster anti-CD3 (Serotec,
1:500), rat anti-CD19 (Serotec, 1:500), goat anti-CD11b
Table 1. Detailed Demographics and Phenotypic Data on Scottish, Cambridge, and Swedish IBD Population
Patients Subclass Scottish Panel Cambridge Panel Swedish Panel
Total number 2,191 (1,374 HC; 474 UC;
335 CD; 8 IBDU)
2,337 (589 HC; 928 UC; 737 CD;
83 IBDU)
774 (281 HC; 288 UC; 205 CD;
0 IBDU)
Sex % male HC 48.7%; UC 52.0%; CD
39.6%
HC 45.0%; UC 52.6%; CD 37.0% HC 45.3%; UC 57.3%; CD 49.8%
Median age (y) at diagnosis/
recruitment (IQR)
HC 50.0 (43.0–55.0); UC
34.1 (25.2–49.9); CD 27.8
(20.8–41.1)
HC 60.0 (53.0–69.0); UC 36.7
(26.84–50.35); CD 26.1
(20.3–37.2)
HC 47.6 (36.4–60.7); UC 28.6
(20.6–41.6); CD 24.5 (19.1–36.7)
CD location Terminal ileum (L1) 35.9% 31.3% 17.4%
Colon (L2) 36.5% 36.5% 47.9%
Ileocolon (L3) 25.1% 30.3% 32.6%
Upper GI disease (L4) 2.5% 1.9% 2.1%
UC location Proctitis (E1) 17.3% 14.8% 10.4%
Left-sided colitis (E2) 40.5% 34.1% 49.5%
Extensive colitis (E3) 42.2% 51.1% 40.1%
CD 5-y behaviour Inflammatory (B1) 64.8% 52.3% 70.9%
Stricturing (B2) 14.8% 35.2% 21.5%
Penetrating (B3) 20.3% 12.5% 7.5%
Perianal involvement (p) 17.4% 24.4% 6.4%
GI, gastrointestinal; IBDU, colonic IBD type unclassified.
doi:10.1371/journal.pmed.0050239.t001
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and rabbit anti–b-galactosidase (a gift of J. Douglas Engel,
Department of Cell and Developmental Biology, University of
Michigan, 1:2,000). All antibody staining was performed over
night at 4 8C, followed by incubation with ﬂuorophore-
labeled Alexaﬂuor secondary antibodies from Molecular
Probes, 1:1,000 for 1 h. Nuclei were counterstained with
DAPI, and slides were mounted in Prolong Gold Antifade
Reagant (Invitrogen). Images were taken using an Olympus
BX51 at 2003 for immunoﬂuorescence and an Olympus
FV500 confocal microscope at 1,0003 for 0.30-lm optical
sectioning.
GLI1 Protein Mutagenesis, Luciferase Assay, and
Immunofluorescence
GLI1 E1100 was ampliﬁed from Image Clone number
3531657, and cloned into pCMV-Tag2b, adding an N-
terminal FLAG motif. GLI1 Q1100 was obtained by inducing
a point mutation using the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene) following the manufacturer’s
protocol. Plasmids encoding 8xGli-Luciferase, m8x Gli-
Luciferase (mutated Gli sites), and Gli2DN were gifts of
Andrzej Dlugosz (University of Michigan). 293T cells were
plated in 12-well plates, transfected with 0.7 lg/well tran-
scription factor, 0.4 lg/well reporter plasmid, and 2 ng/well
pRL-TK Renilla (Promega), and analyzed for luciferase
expression 36 h after transfection using the Dual-Luciferase
Reporter kit (Promega) following the manufacturer’s proto-
col. Fireﬂy luciferase expression was normalized by well to
Renilla, and fold changes were calculated by comparing to
8xGli-Luciferase transfected alone. Statistical analysis was
performed using the Student’s t-test. For immunoﬂuores-
cence, 293T cells grown on collagen-coated coverslips were
transfected with 1.5 lg/well of transcription factor and
analyzed after 36 h. FLAG-tagged GLI1 isoforms were
detected with mouse-anti-FLAG (Sigma) and anti-mouse
AlexaFlour488 (Molecular Probes) both at 1:1,000.
Cytokine Expression QPCR
Colonic tissue was carefully cleaned of all fatty tissue and
whole colonic mRNA was collected using Trizol, followed by
RNA clean-up with DNase digestion using the RNeasy Mini
Kit (Qiagen). cDNA was synthesized using the iScript cDNA
synthesis kit (Biorad), and SybrGreen QPCR was performed
on a Biorad iCycler. Expression levels were normalized to
GAPDH, and statistical analysis was performed using the
Student’s t-test.
Statistical Analysis
Haplotype frequencies of the tSNPs were inferred using the
expectation-maximization algorithm and these used to test
whether haplotype frequencies were different in cases and
controls as implemented in the EH and PM programmes. The
test statistic 23(lnLcase]þln[Lcontrol] – ln[Lcase/Lcontrol]),
which has a v
2 distribution with n   1 degrees of freedom
(where n¼number of possible haplotypes) was calculated and
empirical p-values obtained by permuting the data 10,000
times. Haplotypes were examined and linkage disequilibrium
between individual SNPs (r
2) calculated using the Haploview
programme v3.2 (http://www.hapmap.org). Individual SNP
analysis was performed using v
2 or Fisher’s exact test, where
appropriate, with two-tailed p-values given and odds ratios
(OR) presented with 95% conﬁdence intervals (CIs). The
meta-analysis of SNP rs2228226 was performed using the
Mantel-Haenszel method using a ﬁxed effects model (R-
software package). Details for calculation of false positive
report probability (FPRP) are provided in Supporting
Information (Text S1). Expression proﬁles were analysed
using Mann-Whitney U-test and Kruskal-Wallis test, assuming
a nonparametric distribution of all datasets (GraphPad Prism
4, GraphPad Software Inc.).
Results
Gene-Wide Variation in GLI1 Is Associated with IBD and
Attributable to a Nonsynonymous SNP (rs2228226) in the
Scottish Population
Four multi-marker tSNPs (r
2   0.8) were identiﬁed
(rs3817474, rs2228225, rs2228224, and rs2228226) to describe
haplotypic variation of GLI1, detecting haplotypes of a
frequency .1%. We genotyped these four tSNPs in a Scottish
IBD population consisting of 474 UC and 335 CD cases, and
1,364 well-matched HCs (Table 1). We then used a model-free
analysis [30] to test the association of GLI1 and IBD
susceptibility. In the Scottish population, we demonstrate a
highly signiﬁcant association in IBD (p , 0.0001) and UC (p ,
0.0001), and an association with CD of borderline signiﬁcance
(p ¼ 0.03). On analysis of individual estimated haplotype
frequencies in Haploview, three common haplotypes were
described (A to C; Table S1). We conﬁrmed that this effect
was conﬁned to the GLI1 gene by genotyping an additional
seven haplotype-tagging SNPs, chosen from Phase II HapMap
data, to tag neighbouring blocks, in 166 CD and 170 UC
patients. This conﬁrmed the presence of a GLI1 spanning
haplotype block that did not extend into neighbouring genes
(INHBE and ARHGAP9) (Figure S2).
The association on haplotype testing and log-likelihood
analysis was largely attributable to a nonsynonymous SNP in
exon 12 of GLI1 (rs2228226C!G; tSNP4). rs2228226 was
associated with IBD (allelic frequency OR¼1.23, CI 1.07–1.40,
p ¼ 0.0026; homozygotes OR ¼ 1.56, CI 1.15–2.11, p ¼ 0.0047),
CD (allelic frequency OR ¼ 1.30, CI 1.08–1.55, p ¼ 0.0053,
homozygotes OR ¼ 1.79, CI 1.21–2.65, p ¼ 0.0048), and UC
(allelic frequency OR ¼ 1.19, CI 1.01–1.39, p ¼ 0.04;
homozygotes OR ¼ 1.41, CI 0.98–2.03, p ¼ 0.079) (Tables 2
and S2). These data suggest an allele speciﬁc dose response
with a greater OR for homozygotes than heterozygote
patients. Mutation screening of the GLI1 coding regions by
direct sequencing failed to identify any novel SNPs. There
was no association between seven additional GLI1 variants
from dbSNP and IBD (Table S2). Despite tight linkage
disequilibrium (LD) across GLI1 (Figure S2), there was notably
less LD between rs2228226 and other tSNPs (r
2¼0.7) in both
cases and controls (Figure S3), and this ﬁnding is likely to
provide the explanation for the lack of association in
neighbouring SNPs.
Replication of GLI1 Association in Two Independent
Northern European IBD Cohorts and Meta-Analysis
We then sought to replicate these ﬁndings in other
populations. In a large IBD panel from Cambridge, England
(n ¼ 928 UC, 737 CD, 83 IBDU, and 589 HC) association with
GLI1 was replicated by log-likelihood analysis in IBD (p ¼
0.009) and UC (p , 0.0001). rs2228226 was associated with
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1.03–1.42, p¼0.017), but not CD in this population (Table 2).
As in Scotland, there was no association with tSNPs1 3. Minor
allelic frequencies differed slightly from the Scottish pop-
ulation; this difference is in keeping with that noted for a
number of SNPs analysed for population stratiﬁcation in the
WTCCC study [3]. In the smaller Swedish cohort (n ¼ 770),
there was a consistent trend to association of rs2228226 with
IBD (OR 1.14, CI 0.90–1.45) (Table 2) although this association
was not statistically signiﬁcant. However, the allelic frequen-
cies in cases and controls were very similar in Scotland and
Sweden indicating that the lack of statistical signiﬁcance in
the latter cohort is due to insufﬁcient statistical power. There
were no consistent genotype–phenotype associations across
the populations, including stratiﬁcation for colonic IBD.
A meta-analysis of Scottish, English, and Swedish data for
rs2228226, using the Mantel-Haenszel method with a ﬁxed
effects model on IBD versus HCs (OR 1.194, CI 1.089–1.309, p
¼0.0002) (Figure 1A) conﬁrmed the association of this variant
in Northern Europe, achieving criteria for signiﬁcance in a
gene-centric study [31,32]. The meta-analysis was repeated
separately for UC cases versus HCs with a similar effect size
noted (OR 1.196, CI 1.077–1.327, p ¼ 0.0008) (Figure 1B).
Recognising the current problem with the publication of
false positive ﬁndings in genetic association studies we
estimated the probability that the association with disease
risk found in the meta-analysis of GLI1 SNP rs2228226
represents a true (rather than false positive) association by
adopting the FPRP approach described by Wacholder [33].
This gives an estimated probability that these ﬁndings
represent a true ﬁnding of at least 92% (FPRP , 0.08). This
method is designed to avoid over-interpretation of statisti-
cally signiﬁcant ﬁndings that are not likely to signify a true
positive. In our study, this parameter gives clear support to
our interpretation of these data.
The GLI1 Variant Encoded by rs2228226 Is Functionally
Deficient in Activating GLI-Responsive Transcription In
Vitro
rs2228226C!G is a missense mutation in exon 12 of GLI1,
encoding a change from glutamine to glutamic acid (Q1100E).
The mutation falls within a well conserved motif at the C
terminus of mammalian GLI1 proteins, near a recognized
transactivation domain (Figure 2A) [34]. The Q1100 residue is
itself 100% conserved in all mammals examined (Figure 2B).
In order to evaluate the functional consequences of the
Q1100E mutation, we transfected either GLI1 Q1100 or the
variant GLI1 E1100 into 293T cells. No signiﬁcant differences
in level of expression or cellular localization were detected
between these GLI1 variants; both proteins were readily
detectable in the nucleus of transfected cells (Figure 2C and
2D). Blinded quantitation of cellular localization demonstra-
ted a range of cytoplasmic and nuclear localization that was
similar for both GLI1 variants (unpublished data). We further
evaluated the ability of each variant to activate the well-
characterized GLI reporter 8xGli-Luciferase [35]. We utilized
Gli2DN, a very strong activator of 8xGli-Luciferase, as a
positive control for GLI1 transcriptional activity [36]. While
both GLI1 variants activated 8xGli-Luciferase above baseline,
WT GLI1 Q1100 was 2-fold more efﬁcient as a transcriptional
activator than the variant GLI1 E1100 (Figure 2E).
HH Pathway Activity Is Dysregulated in Colonic
Inflammation
Extended in silico analysis of microarray data demonstrates
that mRNA transcripts of PTCH and hedgehog-interacting
protein (HHIP), along with HH protein, are greater in the
distal compared with the proximal colon in humans, mirror-
ing the expression gradient of GLI1 previously reported [26]
(Figure 3A and 3B). GLI1, PTCH, and HHIP are pathway
response elements whose expression levels predict pathway
activity [14]. GLI1 (p¼0.0003), PTCH (p¼0.002), and HHIP (p
¼0.0003) were lower in inﬂamed UC compared with HC from
equivalent location (Figure 3C). IHH was lower in UC
regardless of inﬂammation (p ¼ 0.02). GLI1 expression was
lower in CD than HC (p¼0.004) irrespective of inﬂammatory
status (Figure 3D), a noteworthy ﬁnding given that GLI1
variation was also associated with CD in Scotland. PTCH was
lower in inﬂamed CD compared with noninﬂamed CDand HC
(p ¼ 0.007) (Figure S5). GLI1 and PTCH were both lower in
non-IBD inﬂammation versus HC (Figures 3D and Figure S6).
Treatment for IBD (5-amino salicylic acid, thiopurines, and
corticosteroids) did not inﬂuence expression of GLI1 (Figure
S7). These data demonstrate overall down-regulation of HH
pathway activity, including GLI1, PTCH, and HHIP, in areas of
colonic inﬂammation.
Gli1
þ/lacZ Animals Exhibit Mortality and Heightened
Morbidity in Response to Intestinal Inflammation Induced
by 3% DSS Treatment
In vitro analysis of the GLI1 1100E variant demonstrated a
50% deﬁciency in transactivation function compared to WT
Table 2. Minor Allelic Frequencies for GLI1 Nonsynonymous SNP rs2228226 (tSNP4) in Scottish, English, and Swedish HC, IBD, CD, and
UC
Population HC IBD UC CD
n Percent n Percent p-Value, OR (CI) n Percent p-Value, OR (CI) n Percent p-Value, OR (CI)
Scotland 1,374 30.3 884 34.8 0.0026, 1.23 (1.07–1.40) 474 33.9 0.042, 1.19 (1.01–1.39) 335 36.1 0.0053, 1.30 (1.08–1.55)
Cambridge 589 26.4 1,737 29.6 0.042, 1.17 (1.00–1.36) 928 30.8 0.017, 1.21 (1.03–1.42) 737 27.9 0.40, 1.08 (0.90–1.28)
Sweden 281 30.6 493 35.0 0.27,1.14 (0.90–1.45) 288 34.4 0.43, 1.11 (0.90–1.45) 205 35.9 0.24, 1.19 (0.90–1.58)
ORs and two-tailed p-values are given for v
2 analysis of IBD versus HC, UC versus HC, and CD versus HC in each of these three populations. Meta-analysis of these data are presented in
Figure 1. Frequencies of estimated haplotypes in all three populations and the full genotype data for the Scottish population are detailed in Supporting Information materials (Tables S1
and S2).
doi:10.1371/journal.pmed.0050239.t002
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GLI1 and Inflammatory Bowel DiseaseGLI1 and our genetic analysis demonstrated an allele-speciﬁc
dosage response, suggesting that a moderate reduction in
GLI1 function may predispose to intestinal inﬂammatory
disease. To speciﬁcally test this hypothesis, we treated
Gli1
þ/lacZ mice [37] and their WT littermates with 3% DSS to
induce acute intestinal inﬂammation.
Gli1
þ/lacZ animals were rapidly and severely affected by DSS
treatment. After 6 d, four out of nine had died, and three of
the survivors demonstrated severe morbidity, with signiﬁcant
rectal bleeding and almost complete immobility (Figure 4A).
In contrast, no WT animals (n¼14) died, all were mobile and
showed less morbidity on days 5 and 6 after treatment.
Gli1
þ/lacZ animals developed bloody diarrhoea and signiﬁcant
weight loss by day 4, whereas WT animals did not develop
clinical signs or measurable weight loss until day 6 (Figure 4B
and 4C). The rapid onset of weight loss, clinical signs, and
mortality in Gli1
þ/lacZ animals was potentially indicative of
extensive colonic inﬂammation, leading us to directly assess
the histology of Gli1
þ/lacZ and WT colons after DSS admin-
istration.
Gli1
þ/lacZ Animals Develop More Severe Colonic Pathology
Than WT Littermates in Response to DSS Treatment
Untreated WT and Gli1
þ/lacZ animals had intact colonic
mucosa; no clinical or histological signs of inﬂammatory
disease were present prior to DSS treatment (Figure 5A and
5B). After 4 d of DSS treatment, WT colons exhibited
evidence of inﬂammatory change but with few destructive
lesions (Figure 5C), while extensive inﬂammatory inﬁltration
and destructive colonic ulcers were prominent in Gli1
þ/lacZ
mice (Figure 5D). After 6 d, the number, size, and invasiveness
of inﬂammatory lesions (Figure 5E–5G) were signiﬁcantly
greater in Gli1
þ/lacZ animals, and the overall colitis score
(Figure 5H) [29] was signiﬁcantly greater. Taken together,
these results demonstrate that the loss of a single Gli1 allele
leads to increased sensitivity to DSS treatment as reﬂected by
severe intestinal inﬂammatory pathology and clinical signs.
Intestinal Myeloid Cells Respond Directly to HH Signals
We previously demonstrated that HH signalling is para-
crine in murine intestine and colon [38]. Given that Gli1
þ/lacZ
animals contain a copy of bacterial b-galactosidase under the
control of the Gli1 promoter, they represent an excellent
model to conﬁrm this observation and identify cell types that
are Hh-responsive (i.e., LacZ positive) before and during
inﬂammatory disease. These studies revealed that no auto-
crine Hh signalling was detectable in untreated adult colon or
following inﬂammatory stress; colonic epithelial cells do not
express Gli1 or respond to Hh signals during colonic
homeostasis or in areas of either mild or severe epithelial
perturbation (Figure 6 and unpublished data). We did,
however, detect a large population of Hh-responsive cells
within the inﬂammatory inﬁltrate of DSS-induced ulcers after
4 d of DSS treatment in Gli1
þ/lacZ animals (Figure 6D–6F).
Both lymphocytes [21,22] and myeloid cells [23] have recently
been shown to respond to Hh signals outside of the
gastrointestinal tract. We therefore investigated whether
these populations were responding in the adult colon. We
detected CD3-positive T lymphocytes, CD11b-positive mye-
loid cells, and CD11c-positive dendritic cells responding to
Hh signalling in resting colon without DSS treatment (Figure
6A–6C). After 4 d of DSS treatment, signiﬁcant numbers of
Hh-responsive myeloid and dendritic cells were seen in
inﬂammatory ulcers (Figure 6E and 6F). We did not detect Hh
response amongst the inﬁltrating T cells in DSS-induced
ulcers (Figure 6D). Examination of CD19-postive B lympho-
cytes in resting colon and after both 4 and 6 d of 3% DSS
treatment revealed no clear Hh response in this population
(unpublished data). Taken together, these data suggest that
myeloid cells, including dendritic cells, are direct targets of
Figure 1. Meta-Analysis of Nonsynonymous GLI1 SNP rs2228226 (tSNP4)
in Scotland, Cambridge, and Sweden Using Mantel-Haenszel Method (n¼
5,352 Individuals)
(A) IBD versus HCs.
(B) UC versus HCs. There was no evidence of heterogeneity in the
contribution of rs2228226 between the three cohorts (p¼0.825). 95% CIs
for individual populations are represented by horizontal lines and
population sizes by square boxes. The diamond represents the pooled
OR (fixed effect model) with 95% CIs delineated by the diamond’s width.
Note the different range of the x-axis for (A) and (B).
doi:10.1371/journal.pmed.0050239.g001
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GLI1 and Inflammatory Bowel DiseaseHh signalling in the colon both during homeostasis and after
inﬂammatory stress. This ﬁnding, in association with the
ﬁndings above, implies that direct Hh signalling may play a
role in innate immune function in the colon.
Gli1
þ/lacZ Animals Have Dramatically Increased IL-23p19
and Pro-inflammatory Cytokine Expression after DSS
Treatment
Overall, unchallenged WT and Gli1
þ/lacZ animals have a
similar cytokine and chemokine proﬁle as determined by
QPCR examination of whole colonic tissue (Figure 7A). There
are, however, several molecules (Cxcl2, Cxcl5, Cxcl10, and
Arg1) that are modestly increased in Gli1
þ/lacZ animals, and a
small decrease in IL-6 expression; these changes may indicate
a subtle difference in the inﬂammatory milieu of Gli1
þ/lacZ
animals at baseline. More strikingly, after 6 d of DSS Gli1
þ/lacZ
animals demonstrate robustly up-regulated expression of
several pro-inﬂammatory cytokines and chemokines com-
pared to WT (Figure 7B). When baseline expression values are
compared to values after DSS challenge for each genotype
(Figure 7C), robust expression and up-regulation of TH1
cytokines, including IFNc, is detectable in Gli1
þ/lacZ animals
(Figure 7B and 7C). We did not detect a signiﬁcant difference
in TGFb and IL-10 between Gli1
þ/lacZ and WT animals,
suggesting that down-regulation of anti-inﬂammatory cyto-
kines was not the primary mechanism of increased inﬂam-
mation in this model.
The most highly expressed cytokine after DSS treatment in
Gli1
þ/lacZ animals was IL-23p19, a molecule that drives
differentiation of TH17 lymphocytes, key mediators of
inﬂammation in several systems, including IBD [39,40]. IL-
12 and IL-17, cytokines closely associated with IL-23, were
also robustly up-regulated in Gli1
þ/lacZ animals. In fact, this
entire pathway was highly up-regulated from the baseline in
Figure 2. Q1100E Disrupts a Conserved Region of the GLI1 Protein and Reduces GLI1 Transcriptional Activity
(A) Conservation of known functional domains in the Gli1 protein. Previously described Sufu binding, DNA binding, and transactivation domains
[34,57,58] are shown schematically. Amino acid conservation of each domain is represented numerically and by shading of the bar below the domain.
Red boxes indicate regions known to regulate GLI1 protein stability [49]. The conserved C-terminal domain that includes Q1100E is adjacent to a known
transactivation domain.
(B) Alignment of the C terminus of mammalian Gli1 proteins. This region (AA 1080–1106) is highly conserved in mammalian lineages.
(C, D) GLI1 Q1100 and E1100 have similar cellular localization in 293T cells.
(E) GLI1 E1100 is deficient in driving activation of the 8xGli-Luciferase reporter compared to GLI1 Q1100. GLI2DN is a strong activator of 8xGli-Luciferase
and serves as a positive control for GLI1 activation. The m8xGli-Luciferase construct contains eight mutant Gli binding sites and serves as a negative
control. Data are shown from six triplicate experiments done using two different plasmid preparations (n ¼ 18). Bar heights indicate mean fold
activation above baseline, and error bars indicate standard error of the mean. p-Values were calculated using the Student’s t-test.
doi:10.1371/journal.pmed.0050239.g002
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GLI1 and Inflammatory Bowel DiseaseFigure 3. Expression of HH Signalling Components in the Healthy Human Adult Colon (HC) and UC
(A) PTCH, HHIP, and GLI1 mRNA levels increase along the length of the healthy adult colon, from ascending colon (AC) to descending colon (DC) and
sigmoid colon (SC).
(B) HH protein expression in terminally differentiated enterocytes at the luminal surface, is greater in the distal colon compared with the proximal
(vertical and horizontal arrows represent these gradients).
(C) Quantitative analysis of mRNA levels of IHH, PTCH, GLI1, and HHIP in UC compared with noninflamed HC (HC N-I). To account for the gradients
identified along the length of the healthy colon (a-b), the data from SC only are shown. QPCR data is presented for IHH as this gene was not present on
the Agilent microarray chip.
(D) GLI1 expression in CD versus HC (N-I) and non-IBD inflammation (HC I) versus HC. Disease specimens are subcategorised into noninflamed (N-I) and
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þ/lacZ animals compared to WT littermates (Figure 7B and
7C). These ﬁndings are particularly interesting since the IL-23
pathway has recently been strongly implicated in IBD
pathogenesis both in humans [4] and mice [40]. Taken
together, these cytokine data conﬁrm that animals lacking
one genomic copy of Gli1 develop signiﬁcantly increased
inﬂammatory disease compared to WT littermates in re-
sponse to the same inﬂammatory challenge.
Discussion
The data presented here provide the ﬁrst evidence, to our
knowledge, that intact HH signalling is critical in the
mammalian gut response to inﬂammatory challenge, and
suggest that reduced GLI1 function is implicated in IBD
pathogenesis. We conﬁrm that the HH signalling pathway is
down-regulated in colonic inﬂammation in humans. We
identify a speciﬁc GLI1 variant that is highly associated with
UC/IBD, and demonstrate that the variant protein is func-
tionally deﬁcient as a transcriptional activator in vitro.
Finally, we demonstrate that mice with a 50% reduction in
Gli1 exhibit a heightened intestinal inﬂammatory response to
DSS with signiﬁcant up-regulation of the IL-23 pathway. Not
only do these ﬁndings have clear implications for the
understanding of IBD pathogenesis and suggest potential
for therapeutic intervention, they are the ﬁrst clear descrip-
tion of a functional role for HH signalling and GLI1 in bowel
inﬂammation.
The inherited variation in the GLI1 gene that we have
detected is associated with IBD and UC, in both Scotland and
England, with ﬁndings for rs2228226 conﬁrmed by meta-
analysis of over 5,000 individuals, with OR of 1.19. Evidence
for an effect in CD is seen in the present study, but the
predominant effect is clearly related to UC, consistent with
the reported IBD2 linkage studies [11,13]. The magnitude of
this association is entirely in line with the effect size noted in
a number of recent studies of complex disease genetics,
including CD [41], colo-rectal cancer [42], and coeliac disease
[43]. The level of signiﬁcance attained satisﬁes suggested
criteria of p , 10
 4 to 10
 6 for gene-centric studies [31,32].
Population heterogeneity has been previously described at
the IBD2 linkage region [11,13,44,45]. The three Northern
European populations studied here have previously demon-
strated similar contribution of other IBD susceptibility genes/
loci, including NOD2 and IBD5 [46].
Whilst our resequencing efforts identify rs2228226 as the
only coding variant associated with IBD, further deep
resequencing will be important in the future as the haplotype
analysis and log-likelihood analyses raise the possibility that
other germ-line variants may also contribute to IBD risk.
These need be explored formally—speciﬁcally the role of
intronic variants, long-range promoter effects, and/or copy
number variation. In this context, several complex disease
genes, including NOD2 [8,9], have multiple independent
mutations conferring disease risk, some disease genes have no
causative mutations within coding sequences (e.g., IRGM in
CD [10,47]), and synonymous SNPs may be associated with
functional effects [48].
rs2228226C!G encodes a change from glutamine to
glutamic acid (Q1100E). Our in vitro data demonstrate that
GLI1 1100E is a subfunctional transcriptional activator
compared to WT GLI1, though it is appropriately synthesized
and localized. The Q1100E mutation causes a signiﬁcant
charge change in a conserved region directly adjacent to the
known transactivation region of GLI1; this change could
directly modify transactivation activity, disrupt the structure
of the transactivation domain, or affect protein stabilization
[49], decreasing activity. Our murine data conﬁrm that
inflamed (I) tissues. There was no change in levels of desert HH (DHH), PTCH2, GLI2, GLI3, SUFU, or DISP1 in either UC or CD compared with HC, or in
non-IBD inflammation (unpublished data). Analysis of SHH mRNA demonstrated a mild increase in expression levels related to inflammation that is
consistent with the known expression of SHH in inflammatory cells (Figure S4) [21]. Individual data points are plotted with horizontal lines representing
the medians for each dataset. p-Values presented are derived from Kruskal-Wallis test, comparing levels in AC, DC, and SC, and from Mann-Whitney U-
tests (UC versus HC (N-I)).
doi:10.1371/journal.pmed.0050239.g003
Figure 4. Gli1
þ/lacZ Animals Show Mortality, Severe Clinical Symptoms, and Profound Weight Loss after DSS Treatment
(A) Kaplan-Meier survival curve. WT animals are 100% viable over the 6-d treatment period (n¼14). Nearly 50% of Gli1
þ/lacZ animals (four out of nine) die
in response to 3% DSS treatment for 6 d.
(B) Gli1
þ/lacZ animals display markedly more severe symptoms than WT animals after 4 or 6 d of 3% DSS treatment. 1, diarrhoea; 2, bloody diarrhoea; 4,
severe bleeding/death. Each dot represents an individual animal and the solid line shows the mean observation in each cohort.
(C) Gli1
þ/lacZ animals (n ¼ 9) lose weight more rapidly than their WT littermates (n ¼ 10). *, p , 0.05 by Student’s t-test.
doi:10.1371/journal.pmed.0050239.g004
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þ/lacZ Animals Demonstrate More Severe Intestinal Inflammation than WT Littermates in Response to DSS Treatment
(A, B) WT and Gli1
þ/lacZ animals demonstrate normal thickness and structure of colonic mucosa in the absence of DSS.
(C) WT animals (n ¼4) exhibit mild colonic inflammation but do not develop substantial epithelial or ulcerative inflammatory pathology within 4 d of
DSS treatment.
(D) Gli1
þ/lacZ animals (n ¼ 4) develop significant inflammatory infiltration, epithelial damage, and ulceration within 4 d of DSS treatment.
(E) WT animals (n ¼ 14) demonstrate ulceration following DSS treatment.
(F) Gli1
þ/lacZ animals develop profound intestinal inflammation in response to 3% DSS treatment, with severe epithelial damage in long stretches of their
colonic mucosa (n ¼ 9).
(G) Blinded histological scoring of colonic damage after 6 d of DSS treatment. Standard lengths of tissue from the mid colon and distal descending
colon were scored in each animal. Gli1
þ/lacZ animals (n¼6) have more overall inflammatory foci and more long foci (10þcrypt units affected) than WT
animals (n¼6). Each dot represents the number of observed foci in an individual animal; the solid line shows the mean observation in each cohort. Red
dots indicate the animals that were analyzed for cytokine expression.
(H) Comprehensive colitis scoring [29] of WT and Gli1
þ/lacZ animals after 4 and 6 d of DSS treatment. p-Values for (G) and (H) calculated by the Student’s
t-test.
doi:10.1371/journal.pmed.0050239.g005
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GLI1 and Inflammatory Bowel Diseasereduction in GLI1 activity has signiﬁcant consequences for
the inﬂammatory response.
Intestinal HH signalling in mice and humans is exclusively
paracrine: HH ligands in the epithelium signal to the HH
response network (PTCH, GLI1, HHIP) in the mesenchyme
[38,50,51]. This has been demonstrated during development
[38], homeostasis (Kolterud A, Grosse AS, Zacharias WJ,
Walton KD, and Gumucio DL, personal correspondence),
malignancy [51], and now, in this report, in inﬂammation.
The human expression data presented here also support the
relevance of the HH pathway to colonic inﬂammation in
humans. GLI1 expression, a reliable indicator of pathway
activity, is down-regulated in all forms of colonic inﬂamma-
tion examined (UC, CD, and non-IBD inﬂammation). Whilst
Figure 6. Intestinal Myeloid Cells Respond Directly to Hh Signalling during Homeostasis and Inflammation
(A–C) No DSS treatment.
(D–F) 4 d of 3% DSS.
(A, D) Few CD3þ T lymphocytes respond to Hh signalling during colonic homeostasis. Infiltrating T cells in DSS-induced ulcers do not express Gli1 or
respond to Hh signalling.
(B, E) Many but not all CD11bþ myeloid cells respond to Hh signalling and express LacZ. After 4 d of DSS, ulcers in Gli1
þ/lacZ animals are filled with
myeloid cells, many of which respond to Hh signals.
(C, F) CD11cþdendritic cells respond directly to Hh signals during homeostasis and inflammation. Nuclear DAPI staining was performed but has been
omitted to allow clear visualization of co-expression of nuclear LacZ and cell surface markers.
doi:10.1371/journal.pmed.0050239.g006
Figure 7. Cytokine Analysis of Gli1
þ/lacZ and WT Mice after DSS Treatments Demonstrates Robust Pro-inflammatory Cytokine Activation
(A, B) Cytokine and chemokine expression normalized to GAPDH is plotted on the y-axis for Gli1
þ/lacZ mice, and on the x-axis for WT animals. Gene
expression levels that are statistically different are shown with stars. The dotted diagonal trend line indicates identical expression levels between WT
and Gli1
þ/lacZ mice. (A) Cytokine and chemokine expression in WT and Gli1
þ/lacZ animals (n ¼ 3) without DSS treatment. Cytokine and chemokine
expression is low and very similar between WT and Gli1
þ/lacZ animals.
(B) Cytokine expression in WT and Gli1
þ/lacZ animals (n ¼ 4) after 6 d of 3% DSS treatment. Many pro-inflammatory cytokines and chemokines are
significantly more highly expressed in Gli1
þ/lacZ animals compared to WT. Note the difference in axes in panels (A) and (B).
(C) Fold change of cytokine expression from baseline to inflamed for WT and Gli1
þ/lacZ animals. We detect dramatic up-regulation of Th17 and Th1
pathway cytokines and chemokines in Gli1
þ/lacZ animals. *, p , 0.05; **, p , 0.01 by the Student’s t-test.
doi:10.1371/journal.pmed.0050239.g007
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GLI1 and Inflammatory Bowel Diseaseembryonic HH pathway activity is reportedly recapitulated in
diverse organs/tissues in response to acute injury and
inﬂammatory challenge [15–19], GLI1 expression is notably
decreased in psoriasis, a disease of the epithelial border that
shares some pathogenic features with IBD [52].
The localisation of HH protein demonstrated here is
similar to that shown for IHH by van den Brink and
colleagues by in situ hybridisation [53]. However, along with
other commentators, we would urge caution in the use of the
commercially available HH pathway antibodies presently
available [54]. We note further that the expression analysis
of disease samples in humans is inherently limited in that it
only depicts a complex process at a late time point in
established disease. Nonetheless, in combination with studies
utilizing models (such as the Gli1
þ/lacZ mouse) to directly
correlate HH response with inﬂammatory challenge, these
studies provide useful information to help elucidate the
aetiology of human inﬂammatory disease.
Gli1
þ/lacZ animals, which have only 50% of the WT level of
Gli1, develop severe and rapid inﬂammation in response to
DSS, despite having normal histological structure and a
largely WT cytokine and chemokine proﬁle prior to DSS
treatment. These data, to our knowledge, provide the ﬁrst
description of a phenotype for reduced Gli1 function [37], and
demonstrate the key role that a full complement of Gli1 plays
in protection from inﬂammatory disease. Our in vitro data
demonstrate that GLI1 E1100 is capable of activating some
GLI1 response, suggesting that under homeostatic conditions,
GLI1 E1100 could performadequately. Similar to thesituation
in Gli1
þ/lacZ animals, however, under conditions of inﬂamma-
torystress, GLI1 E1100 can only function at 50% of the level of
WT GLI1. Whether the predisposition to inﬂammation in
these systems is a direct result of lowered HH signal
transduction within HH-responsive inﬂammatory cells or
reﬂects the effect of lower HH signals on other stromal target
cells [15] that, in turn, release signals that impact the integrity
of the epithelial layer or the inﬂammatory phenotype of
resident immune cells is not yet clear, and will be an
important area of future study. Furthermore, we believe that
it will be important to determine if other primary (e.g., germ-
line variation in other HH pathway genes and the HH
interactome, epigenetic changes, and gene–environmental
interactions) or secondary phenomena (e.g., due to alterations
in commensal ﬂora) in the human/murine intestine alter the
transduction of HH signals in response to acute and chronic
inﬂammatory challenge.
We have additionally shown that the HH pathway may
directly modify the innate immune response through signal-
ling to myeloid target cells. This ﬁnding is in accord with
recent data demonstrating a crucial role for Hh signalling in
myeloid cell maturation in the spleen [23]. Interestingly,
myeloid cell populations are known to modify the intestinal
inﬂammatory milieu through a signiﬁcant impact on the IL-
23/IL-17 pathway [55], a pathway that we ﬁnd to be clearly
and distinctly dysregulated in Gli1
þ/lacZ inﬂammation. Taken
together, these data raise the exciting possibility that the
normal role of HH signalling is to promote a tolerogenic
phenotype in mucosal myeloid cells. In the face of reduced
HH signal transduction in these cells, minor inﬂammatory
stimuli may trigger robust inﬂammatory responses. Future
studies directly investigating this hypothesis by speciﬁcally
testing the effects of Hh signalling on intestinal myeloid cells
will be crucial to the evolution of a more complete under-
standing the role of Hh in intestinal inﬂammation.
Limitations of the Study
A number of issues meriting further work emerge from the
present study. Firstly, deep resequencing of the entire GLI1
gene is required to identify additional variants that contrib-
ute to the overall disease association noted for the gene.
Secondly, the in vivo examination of reduced Gli1 function is
presently limited to heterozygous mice. Despite the robust
phenotype observed in these mice following acute inﬂamma-
tory challenge, these ﬁndings need to be extended to
homozygous null mutant animals (Gli1
 / ). Thirdly, additional
animal models of colitis, particularly of chronic disease, need
to be examined; for example, trinitrobenzene sulfonic acid
(TNBS) induced colitis, or adoptive transfer of
CD4
þCD45RB
high T cells into recombinase-activating gene
(rag)-1 deﬁcient (rag1
 / ) mice. Finally, we have not yet directly
examined the phenotype of reduced GLI1 function in antigen
presenting cells in vitro.
Conclusions
A key paradigm emerging in complex disease genetics is
that gene discovery may lead to fundamental shifts in the
direction of basic and translational research efforts. Recently,
it is apparent that mechanistic insights may have greater
signiﬁcance than the index gene discovery itself, especially
when one considers the small contribution each locus/variant
makes towards disease susceptibility. IBD has provided
several recent examples. Notably, the discoveries of NOD2
and IL-23R have launched academic and pharmaceutical
research efforts into innate immunity and Th17 signalling,
whereas ATG16L1 and IRGM have focused much attention on
the role of autophagy in CD pathogenesis. In the present
study, our genetic studies led in turn to detailed observations
of expression in established human disease as well as a
mechanistic study in the mouse. We believe that these
combined ﬁndings have the potential to open entirely novel
lines of enquiry that may have great consequences for the
understanding of IBD pathogenesis and potentially for
inﬂammatory pathways in other HH-expressing organs (e.g.,
skin, lung, bone).
In conclusion, we demonstrate here the dysregulation of a
developmental signalling pathway in IBD for the ﬁrst time to
our knowledge. Furthermore, we show that these effects are in
part genetically determined, with evidence implicating GLI1
as an IBD2 gene, and identiﬁcation of a speciﬁc variant with
reduced transcriptional activity. The functional relevance of
Gli1 is demonstrated by the severe intestinal inﬂammation
that develops in the face of a 50% reduction in Gli1
concentration in an established mouse model of colitis. Taken
together, these data strongly argue that tolerance to inﬂam-
matory stimuli requires a fully functional HH signal trans-
duction network. With HH signalling modulators under active
investigation in a number of clinical trials (http://www.curis.
com and http://www.clinicaltrials.gov), these data provide
promise for the development of novel therapeutic strategies.
Sincethe use of HH inhibitors has recently been advocated for
the treatment of certain tumours that secrete HH, our ﬁnding
that reduced HH signalling has inﬂammatory consequences
suggests that inﬂammatory status should be carefully followed
during upcoming Phase II trials [56].
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Figure S1. Schematic of Activation Events in the HH Signalling
Pathway
There are three mammalian homologues of Drosophila gene Hh,o f
which SHH and IHH have important functions in the gut and the
immune system. Intestinal HH expression is limited to epithelial cells,
while HH-response genes are expressed only in intestinal mesen-
chyme. In epithelial cells, soluble HH is processed in the Golgi and
released via Dispatched (DISP1). In the mesenchyme, upon HH
binding to the transmembrane receptor PTCH, PTCH can no longer
repress SMO, and SMO prevents cleavage of transcription factors
GLI2 and GLI3 from activator to repressor form; GLI activator forms
then predominate, and transcription is activated in a raft of
downstream targets. Direct early targets of HH signals include
GLI1, a strong transcriptional activator which acts an ampliﬁer of HH
signalling, PTCH, and HHIP, a feedback inhibitor; these markers can
be used as indicators of pathway activity [14,54].
Found at doi:10.1371/journal.pmed.0050239.sg001 (66 KB PPT).
Figure S2. The Haplotype Structure in GLI1 and Surrounding
Haplotype Blocks Are Presented in Haploview from Genotyping in
UC (A) and CD (B)
There is a haplotype block spanning the GLI1 gene that does not
extend into neighbouring genes. LD is described here by D9 values.
Found at doi:10.1371/journal.pmed.0050239.sg002 (1 MB TIF).
Figure S3. The Haplotype Structure of the Four GLI1 tSNPs from the
Scottish HCs and UC Population and from HapMap CEU Data Is
Demonstrated with r
2 Values
The LD between rs2228226 and neighbouring SNPs is overestimated
by D9 (Figure S2). The r
2 value between rs2228226 (tSNP4) and
rs2228224 (tSNP3) in UC is 0.7, providing an explanation for the
evidence of association at rs2228226 in the absence of association at
neighbouring SNPs.
Found at doi:10.1371/journal.pmed.0050239.sg003 (325 KB TIF).
Figure S4. Quantitative Analysis of mRNA Levels by Microarray and
RT-PCR of SHH in UC Compared with Noninﬂamed HCs
For the microarray data on the left, disease specimens are taken from
the ascending colon (AC), descending colon (DC), and sigmoid colon
(SC). To take into account anatomical gradients of HH signalling in
Figure 3, RT-PCR (right) is performed on samples from SC only, and
UC samples are subcategorised into noninﬂamed (N-I) and inﬂamed
(I). This observation validates the microarray data and shows that the
modest increase in SHH is present only with inﬂammation. This
result is of interest given the fact that inﬂammatory cells have been
shown to express SHH. p-Values represent Kruskal-Wallis analysis of
HC versus UC for each anatomical location.
Found at doi:10.1371/journal.pmed.0050239.sg004 (1.9 MB TIF).
Figure S5. Quantitative Analysis of mRNA Levels by Microarray and
RT-PCR of SHH, GLI1, PTCH, and HHIP in CD Compared with
Noninﬂamed HCs
Disease specimens are taken from the terminal ileum (TI), ascending
colon (AC), and sigmoid colon (SC), and are subcategorised into
noninﬂamed (N-I) and inﬂamed (I) tissues. p-Values represent
Kruskal-Wallis analysis of HC, CD (N-I), and CD (I) for each
anatomical location.
Found at doi:10.1371/journal.pmed.0050239.sg005 (1.8 MB JPG).
Figure S6. Analysis of SHH, PTCH, and HHIP mRNA Levels by
Microarray in Colonoscopic Biopsies from the Sigmoid Colon (SC) of
Non-IBD patients with Inﬂammation (I) Compared with Noninﬂamed
HCs (NI)
Found at doi:10.1371/journal.pmed.0050239.sg006 (1.7 MB JPG).
Figure S7. Analysis of GLI1 Expression in UC by Treatment
Data are presented for UC patients on no treatment (Rx), on a 5-
amino salicylic acid (5-ASA) only, on azathioprine (AZA), or
mercaptopurine (MP) with or without a 5-ASA and on steroids (oral
and topical) with or without a 5-ASA. Individual data points are
represented with horizontal lines representing medians. There was
no difference between any of the groups on analysis by Mann-
Whitney U-testing.
Found at doi:10.1371/journal.pmed.0050239.sg007 (932 KB JPG).
Figure S8. The Speciﬁcity of the N-19 HH Antibody Is Demonstrated
with Application of the Primary Antibody, Primary Antibodyþ SHH
Blocking Peptide Pre-absorbed Overnight, and with Primary Anti-
body Omitted
This ﬁgure demonstrates that the N-19 HH antibody reacts with the
peptide but does not preclude it from cross-reacting with other
proteins. Indeed, we would agree with other commentators [54] in
urging caution in the use of this and other presently available HH
antibodies for immunohistochemistry.
Found at doi:10.1371/journal.pmed.0050239.sg008 (289 KB TIF).
Table S1. GLI1 Haplotype Frequencies in IBD, UC, CD, and HC in (A)
Scotland, (B) Cambridge, England, and (C) Sweden
tSNP1, rs3817474; tSNP2, rs2228225; tSNP3, rs2228224; tSNP4,
rs2228226. Differences between IBD, CD, UC, and HC frequencies
are shown, calculated by v
2 test, with two-sided p-value, OR, and 95%
CIs. Estimated haplotype frequencies were calculated using Haplo-
view, version 3.2. Log-likelihood p-values (calculated on the PM/EH
platform with 10,000 permutations and 15 degrees of freedom) are
given for each analysis.
Found at doi:10.1371/journal.pmed.0050239.st001 (61 KB DOC).
Table S2. Details of the 11 GLI1 SNPs Genotyped in the Scottish
Population, Including the Four tSNPs Used for Haplotype Analysis
v
2 analysis for allelic frequency and homozygosity of each tSNP for
UC and CD versus HCs is presented with corresponding p-values, OR,
and 95% CIs. *, n ¼ 370 for SNPs 1–4 and 7–9; U/K, unknown.
Found at doi:10.1371/journal.pmed.0050239.st002 (90 KB DOC).
Text S1. Supplementary Methods
Found at doi:10.1371/journal.pmed.0050239.sd001 (43 KB DOC).
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GLI1 and Inflammatory Bowel DiseaseEditors’ Summary
Background. Inflammatory bowel diseases (IBDs) are common disorders
in which parts of the digestive tract become repeatedly or continuously
inflamed. The immune system normally protects the body from entities it
identifies as foreign, but in IBD it mistakenly recognizes gut tissue, and
immune system cells accumulate in the lining of the bowel, which causes
inflammation. There are two main types of IBD—Crohn’s disease (CD),
which mainly affects the small bowel, and ulcerative colitis (UC), which
affects only the large bowel (colon). Both types tend to run in families
and usually develop between the ages of 15 and 35 years. Symptoms—
including diarrhea, abdominal cramps, and unexplained weight loss—
can be mild or severe and the disease can develop slowly or suddenly.
There is no cure for IBD except surgical removal of the affected part of
the digestive tract. However, drugs that modulate the immune system
(for example, corticosteroids) or that specifically inhibit ‘‘proinflamma-
tory cytokines’’ (proteins made by the immune system that stimulate
inflammation) are often helpful in reducing symptoms.
Why Was This Study Done? Why the immune system becomes
unbalanced in people with IBD is not clear but it is known that IBD is
‘‘polygenic,’’ that is, a disease caused by the combined actions of two or
more inherited gene variants. Although UC and CD are clinically different
diseases, they share several ‘‘susceptibility loci’’ (regions of the genome
that harbor disease-associated gene variants), including the IBD2 locus.
The identification of the actual gene within the IBD2 locus that is altered
in people who are susceptible to IBD might provide new insights into
what causes the immune imbalance in IBD and into how to treat the
disease. In this study, the researchers test the hypothesis that a variant of
a gene called GLI1, which lies in the IBD2 locus, is associated with IBD
susceptibility. GLI1 encodes a transcription factor (a protein that
regulates the production of proteins) that is a central component in
the signaling pathway named for a protein called ‘‘hedgehog.’’ This
pathway is involved in the development of many organs, including the
digestive tract.
What Did the Researchers Do and Find? The researchers used a
technique called gene-wide haplotype tagging to look for inherited GLl1
variants in patients with IBD and in healthy people living in Scotland,
England, and Sweden. A specific variant of the GLI1 gene, resulting in
alteration of a single amino acid component of the GLI1 protein, was
associated with IBD (particularly with UC) in both Scotland and England;
the same variant was weakly associated with IBD in the Swedish
population. The variant GLI1 protein was only half as active as the normal
protein in a laboratory assay, and, consistent with this result, the
expression of several components of the hedgehog signaling pathway
was lower in colon samples taken from patients with UC than in samples
taken from healthy individuals. Finally, Gli1
þ/lacZ mice (which express half
the normal amount of Gli1 protein) developed severe intestinal
inflammation more rapidly than wild-type mice when they were treated
with dextran sodium sulfate (DSS), a chemical that induces acute
(sudden) colitis. Cellular analysis revealed that myeloid cells (cells that
sense and modify the inflammatory response) are direct targets of the
hedgehog signaling pathway. Furthermore, the expression of several
pro-inflammatory cytokines (in particular, one called IL-23) increased
more markedly in the Gli1
þ/lacZ mice than in the wild-type mice after DSS
treatment.
What Do These Findings Mean? These findings suggest that the
normal response of the mammalian gut to challenge with inflammatory
substances involves hedgehog signaling through GLI1 and that reduced
GLI1 function might be one trigger for IBD. More specifically, the human
genetic studies identify a GLI1 variant that is associated with IBD (at least
in certain north European populations), the laboratory experiments
indicate that this GLI1 variant encodes a protein with reduced activity,
and the animal studies show that a similar reduction in Gli1 activity is
sufficient to heighten intestinal inflammatory responses. Although this
last result needs to be confirmed in animal models of chronic colitis that
more closely resemble human IBD, these findings suggest that drugs
that modulate hedgehog signaling might be useful in the treatment of
IBD.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050239.
  The MedlinePlus Encyclopedia has pages on Crohn’s disease and on
ulcerative colitis (in English and Spanish)
  MedlinePlus provides links to other information Crohn’s disease and
ulcerative colitis (in English and Spanish)
  The US National Institute of Diabetes and Digestive and Kidney
Diseases provides information on Crohn’s disease and ulcerative colitis
  The UK National Health Service Direct Encyclopedia also provides
information on Crohn’s disease and on ulcerative colitis
  Wikipedia has a page on the hedgehog signaling pathway (note:
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
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